Compare AstraZeneca plc (AZN) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs GeneDx Holdings Corp — how do they compare? AstraZeneca plc trades at $158.4 (market cap $248.14B), while GeneDx Holdings Corp trades at $82.71 (market cap $2.44B). The key difference: AstraZeneca plc is far larger — about 101.7× GeneDx Holdings Corp's market cap, and AstraZeneca plc pays a 2.01% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| AZN | WGS | |
|---|---|---|
Market Cap | $248.14B | $2.44B |
Sector | Health | Technology |
52-Week High | $209.48 | $167.51 |
52-Week Low | $147.06 | $34.51 |
Enterprise Value | $275.41B | $2.48B |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
GeneDx Holdings Corp (WGS) trades at $82.39, up 5.79% in the past 24 hours, with a bullish technical signal and strong analyst support. The company reported Q2 2026 revenue of $114.4 million, beating guidance, and returned to adjusted profitability earlier than expected. However, net income remains negative at -$106 million for 2026, and the stock faces class action lawsuits with an August 3, 2026 deadline.
Outlook is mixed: bullish technicals and analyst consensus suggest upside to the $90 price target, but fundamental weaknesses and legal risks pose significant challenges. Investment opportunity hinges on sustained revenue growth and margin improvement, while risks include profitability pressures and litigation outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
